Sepracor’s (SEPR) Shares Now Cut In Half

July 27, 2007 by Douglas A. McIntyre

Being in the pharmaceutical development business has always been rough, and investors in Sepracor (SEPR) learned that lesson again today. The company’s shares are down after earnings, off 17% to $31.85. The stock has a 52-week high of $63.24.

For the three months ended June 30, 2007, total revenues increased to approximately $278.1 million, which reflected a 5.2% increase from second quarter 2006 revenues of $264.4 million. Net income for the quarter was approximately $6.1 million, or $0.05 per diluted share compared to $11.0 million, or $0.10 per diluted share for the second quarter of 2006.

Both sales and earnings missed Wall St. hopes.

According to Reuters: Revenue from Lunesta, the company’s popular insomnia drug, grew just slightly, to $143.0 million from $139.1 million a year ago as generic competition weighed.

Generics will hurt a company like SEPR more than its Big Pharma rivals because it has fewer drugs on the market and less in the pipeline. If one product starts to get hit by competition, revenue can be hit hard, and for a long time.

The prospects here look none too good, but neither does the stock price

Douglas A. McIntyre

Take This Retirement Quiz To Get Matched With A Financial Advisor (Sponsored)

Take the quiz below to get matched with a financial advisor today.

Each advisor has been vetted by SmartAsset and is held to a fiduciary standard to act in your best interests.

Here’s how it works:
1. Answer SmartAsset advisor match quiz
2. Review your pre-screened matches at your leisure. Check out the
advisors’ profiles.
3. Speak with advisors at no cost to you. Have an introductory call on the phone or introduction in person and choose whom to work with in the future

Take the retirement quiz right here.

Posted in Investing | No Comments »